- Home
- SLP vs CBIO Comparison
SLP vs CBIO Comparison
Compare SLP & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLP
- CBIO
- Stock Information
- Founded
- SLP 1996
- CBIO 2003
- Country
- SLP United States
- CBIO United States
- Employees
- SLP N/A
- CBIO N/A
- Industry
- SLP EDP Services
- CBIO
- Sector
- SLP Technology
- CBIO
- Exchange
- SLP Nasdaq
- CBIO Nasdaq
- Market Cap
- SLP 286.6M
- CBIO 308.0M
- IPO Year
- SLP 1997
- CBIO N/A
- Fundamental
- Price
- SLP $14.57
- CBIO $15.06
- Analyst Decision
- SLP Buy
- CBIO Strong Buy
- Analyst Count
- SLP 7
- CBIO 4
- Target Price
- SLP $29.50
- CBIO $25.50
- AVG Volume (30 Days)
- SLP 429.3K
- CBIO 99.5K
- Earning Date
- SLP 10-22-2025
- CBIO 07-31-2025
- Dividend Yield
- SLP N/A
- CBIO N/A
- EPS Growth
- SLP N/A
- CBIO N/A
- EPS
- SLP N/A
- CBIO N/A
- Revenue
- SLP $80,383,000.00
- CBIO N/A
- Revenue This Year
- SLP $12.75
- CBIO N/A
- Revenue Next Year
- SLP $3.06
- CBIO N/A
- P/E Ratio
- SLP N/A
- CBIO N/A
- Revenue Growth
- SLP 20.01
- CBIO N/A
- 52 Week Low
- SLP $12.39
- CBIO $10.83
- 52 Week High
- SLP $37.72
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- SLP 50.24
- CBIO 63.38
- Support Level
- SLP $13.70
- CBIO $13.50
- Resistance Level
- SLP $14.88
- CBIO $14.26
- Average True Range (ATR)
- SLP 0.58
- CBIO 0.74
- MACD
- SLP 0.29
- CBIO 0.38
- Stochastic Oscillator
- SLP 86.28
- CBIO 90.58
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.